Upon joining the study, the patient will be assessed to ensure they meet the eligibility criteria. This includes having moderate-to-severe atopic dermatitis and a history of inadequate response to topical treatments.

The patient must agree to apply a moisturizer daily and use authorized topical therapy as needed.

The patient will begin treatment with nemolizumab, administered as a solution for injection under the skin (subcutaneous use).

The dosage and frequency of administration will be determined by the study protocol and the healthcare provider overseeing the trial.

Throughout the study, the patient will receive regular injections of nemolizumab and attend scheduled visits to monitor the safety and effectiveness of the treatment.

The patient will be evaluated for any side effects or adverse events, and their atopic dermatitis symptoms will be assessed using various scales and questionnaires.

The study is designed to assess the long-term safety and efficacy of nemolizumab over a period that may extend up to 200 weeks.

During this time, the patient will continue to receive treatment and attend follow-up visits as outlined in the study schedule.

Upon completion of the study, the patient’s overall response to the treatment will be evaluated.

The patient will be informed about the outcomes and any further steps, if necessary, based on their individual health needs.